Morphogenesis of benign prostatic hyperplasia and prostate carcinoma

被引:12
|
作者
Bonkhoff, H [1 ]
Remberger, K [1 ]
机构
[1] Univ Saarlandes, Inst Pathol, Abt Allgemeine & Spezielle Pathol, D-66421 Homburg, Germany
来源
PATHOLOGE | 1998年 / 19卷 / 01期
关键词
morphogenesis; benign prostate hyperplasia; prostate carcinoma; stem cell model;
D O I
10.1007/s002920050250
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Enlargement of the prostate is an age-related, physiological process that is unique in human tissue. The prostate gland is the most common site of neoplastic disorders in men. Despite the growing impact of the various prostate diseases in terms of morbidity and mortality, the pathogenesis of benign prostate hyperplasia (BPH) and prostate cancer remains poorly understood. This reflects the complex composition of the gland with different anatomic, cellular and functional compartments that are differentially involved in benign and malignant disease processes. The present review summarizes new concepts on the morphogenesis of normal and abnormal growth in the human prostate. There is increasing evidence that prostatic stem cells are located in the basal cell layer that is basically involved in normal growth and the development of glandular hyperplasia and prostate cancer. High-grade prostatic intraepithelial neoplasia is considered the most likely precursor of clinically important cancer of the peripheral zone. Severe differentiation and proliferation abnormalities occur during malignant transformation of the prostatic epithelium. These premalignant changes are associated with abnormal expression of growth factor receptors, oncogene and suppressor gene products and genetic instability. During the process of stromal invasion the transformed cells lose their basal cell phenotype and produce basement membrane-like matrices. Common prostate cancer is mainly composed of exocrine cell types that remain androgen-responsive even in hormone-independent disease. The frequent occurrence of neuroendocrine differentiation in common prostate cancer reflects the differentiation potency of its stem cells. The endocrine phenotype derives from exocrine tumor cells via intermediate (amphicrine) cell types. Neuroendocrine tumor cells consistently lack the nuclear androgen receptor and represent an androgen-insensitive cell population in prostate cancer.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 50 条
  • [1] Benign prostatic hyperplasia and prostate carcinoma in native Africans
    Dawam, D
    Rafindadi, AH
    Kalayi, GD
    BJU INTERNATIONAL, 2000, 85 (09) : 1074 - 1077
  • [2] Zinc status in benign prostatic hyperplasia and prostate carcinoma
    Wiwanitkit, Somsri
    Wiwanitkit, Viroj
    INDIAN JOURNAL OF UROLOGY, 2012, 28 (01) : 115 - 115
  • [3] Benign prostate, prostatic hyperplasia, and prostatic carcinoma in female patients.
    Sesterhenn, IA
    Davis, CJ
    Mostofi, FK
    MODERN PATHOLOGY, 1998, 11 (01) : 95A - 95A
  • [4] Rare Variant of Carcinoma Prostate Masquerading as Benign Prostatic Hyperplasia
    Khanduri, Sachin
    Imam, Tariq
    Khan, Mahar
    Khan, Shahla
    Khan, Ahmad U.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (04)
  • [5] Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma
    O'Neill, AJ
    Boran, SA
    O'Keane, C
    Coffey, RNT
    Hegarty, NJ
    Hegarty, P
    Gaffney, EF
    Fitzpatrick, JM
    Watson, RWG
    PROSTATE, 2001, 47 (03): : 183 - 188
  • [6] ESTROGEN AND ANDROGEN RECEPTORS IN BENIGN PROSTATIC HYPERPLASIA AND CARCINOMA OF THE PROSTATE
    TILLEY, WD
    KEIGHTLEY, DD
    MARSHALL, VR
    BRITISH JOURNAL OF UROLOGY, 1981, 53 (01): : 74 - 74
  • [7] Is diet a risk factor for benign prostatic hyperplasia and carcinoma prostate?
    Naz, Zehra
    Anjum, Saadia
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2010, 26 (04) : 959 - 963
  • [8] NEW TRENDS IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA AND CARCINOMA OF THE PROSTATE
    PETROVICH, Z
    AMEYE, F
    BAERT, L
    BICHLER, KH
    BOYD, SD
    BRADY, LW
    BRUSKEWITZ, RC
    DIXON, C
    PERRIN, P
    WATSON, GM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1993, 16 (03): : 187 - 200
  • [9] Zinc status of patients with benign prostatic hyperplasia and prostate carcinoma
    Christudoss, Pamela
    Selvakumar, R.
    Fleming, Joseph J.
    Gopalakrishnan, Ganesh
    INDIAN JOURNAL OF UROLOGY, 2011, 27 (01) : 14 - 18
  • [10] IMAGING OF THE PROSTATE - BENIGN PROSTATIC HYPERPLASIA
    SCHECKOWITZ, EM
    RESNICK, MI
    UROLOGIC CLINICS OF NORTH AMERICA, 1995, 22 (02) : 321 - 332